{"id":"W2896552337","doi":"10.1002/art.40753","title":"Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase <scp>III</scp> Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors","year":2018,"lang":"en","type":"article","venue":"Arthritis & Rheumatology","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":233,"is_retracted":false,"has_abstract":true,"ca_institutions":"Memorial University of Newfoundland","funders":"Pfizer; National Center for Advancing Translational Sciences; Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Placebo; Randomized controlled trial; Internal medicine; Clinical endpoint; Physical therapy; Disease; Secukinumab; Pathology; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009215731,0.0005653296,0.003917755,0.0008533116,0.0001388075,0.00001980513,0.0001912244,0.0002075742,0.00002092944],"category_scores_gemma":[0.001779715,0.0003664018,0.0003244652,0.001007962,0.001291612,0.0001310261,0.00006145265,0.0001991004,0.000003582769],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009097277,"about_ca_system_score_gemma":0.0002628724,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003085227,"about_ca_topic_score_gemma":0.005966468,"domain_scores_codex":[0.9943793,0.00107042,0.002574197,0.0007927846,0.0005449521,0.0006382818],"domain_scores_gemma":[0.992597,0.005282814,0.0009982897,0.0006314088,0.0002992953,0.0001911333],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9422745,0.007366183,0.008501774,0.00003012934,0.0006865801,0.0002064071,0.01674526,0.000001959292,0.00008524425,0.00002977211,0.00002088689,0.02405127],"study_design_scores_gemma":[0.9313874,0.04041287,0.02368313,0.001679462,0.0002140708,0.00005860916,0.0008675929,0.00001236972,0.001324313,0.00002293487,0.0001757442,0.0001614975],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9834539,0.002663954,0.000007497526,0.0002246048,0.0003037401,0.01265313,0.0006314992,0.0000230125,0.00003864253],"genre_scores_gemma":[0.995187,0.003102861,0.0003230569,0.00003721158,0.00004153277,0.001144048,0.0001046147,0.00004362895,0.00001607857],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03304669,"threshold_uncertainty_score":0.9998788,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01421514111082398,"score_gpt":0.2685552876145689,"score_spread":0.2543401465037449,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}